9/6/2019
ActoBio Announces Phase 1b/2a Trial for ActoBiotics® AG017
ActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.
Continue ReadingActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.
Continue ReadingThe Celiac Disease Foundation is proud to announce that Bradley J. Herrema, Secretary of the Foundation’s Board of Directors, has been selected for recognition as one the 2020 Best Lawyers in America.
Continue Reading